Supernus Pharmaceuticals has been granted a patent for a method of treating aggression, impulsivity, and irritability in patients diagnosed with bipolar disorder or post-traumatic stress disorder. The method involves administering a pharmaceutical agent with combined D2 and D5 antagonistic activity, specifically molindone. GlobalData’s report on Supernus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Supernus Pharmaceuticals, cancer treatment biomarkers was a key innovation area identified from patents. Supernus Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of aggression, impulsivity, and irritability using molindone
A recently granted patent (Publication Number: US11638708B2) describes a method for treating behavioral syndromes such as impulsivity and irritability in mammalian subjects diagnosed with bipolar disorder or post-traumatic stress disorder. The method involves administering a pharmaceutical agent that exhibits combined D2 and D5 antagonistic activity, with the specific agent mentioned in the patent being molindone.
The patent claims specify different aspects of the method. Claim 1 outlines the overall method of treating impulsivity and irritability in subjects diagnosed with bipolar disorder or post-traumatic stress disorder by administering a pharmaceutical agent with combined D2 and D5 antagonistic activity, specifically molindone. Claim 2 focuses on the treatment of impulsivity, while Claim 3 focuses on the treatment of irritability. Claim 4 provides a dose range for administering the agent, ranging from 10 mg/day to 200 mg/day. Claim 5 specifies that the method can be applied to child subjects.
This patent highlights the potential use of molindone, a pharmaceutical agent with combined D2 and D5 antagonistic activity, in the treatment of behavioral syndromes associated with bipolar disorder and post-traumatic stress disorder. The method described in the patent offers a specific dose range for administering the agent and suggests that it can be effective in both adult and child subjects.
It is important to note that this media summary is based solely on the information provided in the patent claims and does not include any additional research or clinical data. Further studies and trials would be necessary to validate the effectiveness and safety of this method in treating impulsivity and irritability in subjects with bipolar disorder or post-traumatic stress disorder.
To know more about GlobalData’s detailed insights on Supernus Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
